Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-07-01 | Reverse | 1:12 |
| 2017-07-20 | Reverse | 1:10 |
Daré Bioscience, a clinical-stage biotech, develops women's health products—including contraceptives, fertility, and vaginal health therapies—such as XACIATO, Ovaprene, and Sildenafil Cream, with several in advanced clinical and pre-clinical stages.
DARE to PLAY is a clinically-backed topical sildenafil cream for women to enhance genital blood flow and sexual response, with commercial launch expected in Q4 2025 through a 503B outsourcing facility.
Following FDA delays on its planned Phase 3 trial, Daré Bioscience strategically pivoted to launch its topical sildenafil cream for female sexual arousal disorder under the FDA's 503B compounding rule. The company announced the commercial rollout and availability for pre-order in December 2025, marking its transition from a clinical-stage to a commercial-stage company and positioning it to generate near-term revenue.
In 2025, Daré Bioscience initiated a significant strategic shift from a purely R&D-focused entity to a commercial-stage company by adopting a dual-path commercialization strategy. This new model involves launching products through the FDA's 503B compounding pathway to generate near-term revenue, while simultaneously pursuing traditional, long-term FDA approval. The first product under this new strategy, DARE to PLAY™ Sildenafil Cream, was on track for a Q4 2025 launch.
New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 ANL | $15.29 | COMPARE |
 PALI | $1.46 | COMPARE |
 CTXR | $0.53 | COMPARE |
 AIMD | $1.36 | COMPARE |
 ADTX | $0.00 | COMPARE |
 FBLG | $1.22 | COMPARE |
 ASBP | $8.86 | COMPARE |
